Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacoscopy-guided treatment in RR AML
NCT06138990Phase 2Recruiting
- Sponsor
- ETH Zurich
- Start
- Sep 2024
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) (2 arms), sponsored by ETH Zurich. Primary endpoint: Complete Response Rate at 28 days. Started Sep 2024; status: recruiting.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06138990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06138990.